Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Feb:97:65-69.
doi: 10.1016/j.jpsychires.2017.11.001. Epub 2017 Nov 16.

Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial

W Vaughn McCall  1 , Sarah H Lisanby  2 , Peter B Rosenquist  3 , Mary Dooley  4 , Mustafa M Husain  5 , Rebecca G Knapp  4 , Georgios Petrides  6 , Matthew V Rudorfer  2 , Robert C Young  7 , Shawn M McClintock  5 , Martina Mueller  4 , Joan Prudic  8 , Robert M Greenberg  9 , Richard D Weiner  10 , Samuel H Bailine  11 , Nagy A Youssef  3 , Laryssa McCloud  3 , Charles H Kellner  12 ; CORE/PRIDE Work Group
Affiliations
Randomized Controlled Trial

Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial

W Vaughn McCall et al. J Psychiatr Res. 2018 Feb.

Abstract

We examined whether electroconvulsive therapy (ECT) plus medications ("STABLE + PHARM" group) had superior HRQOL compared with medications alone ("PHARM" group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the "STABLE + PHARM" group versus the "PHARM" group. The overall study design was called "Prolonging Remission in Depressed Elderly" (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of "STABLE + PHARM" versus "PHARM". Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The "PHARM" group received venlafaxine and lithium. The "STABLE + PHARM" received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. "STABLE + PHARM" patients received 4.5 ± 2.5 ECT sessions during Phase 2. "STABLE + PHARM" group had 7 point advantage (3.5-10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2-12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. CLINICAL TRIALS.GOV: NCT01028508.

Keywords: Continuation therapy; Electroconvulsive therapy; Major depressive disorder; Quality of life; Randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. McCall has been a scientific advisor for Merck, and Israeli Growth Partners, and a consultant to Luitpold Pharmaceuticals, Inc and Multiple Energy Technologies, LLC. Dr. Kellner receives honoraria from UpToDate, Psychiatric Times, and Northshore-LIJ Health System, and is a consultant to Luitpold Pharmaceuticals, Inc. Dr. Husain has received grant support from NIDA, NINDS, NIA, NARSD, Stanley Foundation, Cyberonics, Neuronetics, St. Jude medical (ANS), MagStim, Brainsway, NeoSync, Avanir, Alkermes, and has been a consultant to the Neurological Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration (FDA). Dr. Young is a consultant to the NIH. Dr. Lisanby has received grant support from NINDS, NIBIB, Brain and Behavior Research Foundation, Stanley Medical Research Foundation, Neosync, Nexstim, and Brainsway. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. McClintock has received grant support from the NIH/NIMH, honoraria from TMS Health Solutions and the US Department of Veteran Affairs, and is a consultant to Pearson. Dr. Nagy Youssef received grant support from the Department of Veterans Affairs, and CME honoraria form the Georgia Department of Behavioral Health and Developmental Disabilities. The other authors report no financial relationships with commercial interests.

References

    1. Delis D, Kaplan E, Kramer J, Ober B. Manual. The Psychological Corporation; San Antonio: 2000. California Verbal Learning Test-Second Edition (CVLT-II)
    1. Devanand DP, Dwork AJ, Hutchinson ER, Bolwig TG, Sackeim HA. Does ECT alter brain structure? Am. J. Psychiatry. 1994;151(7):957–970. - PubMed
    1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189–198. - PubMed
    1. Galvez V, Li A, Oxley C, Waite S, de Felice N, Hadzi-Pavlovic D, Kumar D, Page AC, Hooke G. Health related quality if life after ECT for depression: a study exploring the role of different electrode-placements and pulse-widths. Journal of Affective Disorders. 2016;206:268–272. - PubMed
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. - PMC - PubMed

Publication types

Associated data